RPG Life Sciences Q2 FY26 Earnings Results

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients. Presenting below are its Q2 FY26 earnings results.

 

Q2 FY26 Earnings Results

• Revenue from Operations: ₹181.7 crore, up 5.5% YoY from ₹172.2 crore and 7.6% QoQ from ₹168.9 crore in Q1 FY26, driven by strong domestic formulations growth despite slower API export recovery.​

• Total Income: ₹186.22 crore, reflecting a 6.9% YoY increase from ₹174.15 crore, confirming stable topline growth.​

• EBITDA: ₹43.6 crore, down 9% YoY from ₹47.9 crore and up 7.1% QoQ, with margins at 24.0% vs 27.8% in Q2 FY25 impacted by higher R&D and promotional costs.​

• Profit Before Tax (PBT): ₹38.2 crore, down 9.8% YoY, compared to ₹42.4 crore in Q2 FY25, while sequentially up 17% QoQ from ₹32.7 crore.​

• Net Profit (PAT): ₹37 crore, up 825% YoY from ₹5 crore but up 8.4% QoQ from ₹26.3 crore in Q1 FY26.​

• EPS: ₹22.28 per share vs ₹15.90 in Q1 FY26 and ₹2.54 in Q2 FY25, benefiting from a low base and consistent incremental profit performance.​

• EBITDA Margin: 24.0% (down 380 bps YoY) due to input cost volatility and higher investment behind new brand launches.​

 

Business Segment Performance

• Domestic Formulations:

  • Contributed 71% to total revenue.

  • Sales up 13.5% YoY to ₹246.1 crore in H1 FY26, outperforming the Indian pharma market’s 7.7% growth rate.​

• International Formulations:

  • Contributed 19% of total revenue, up 2.1% YoY to ₹67 crore, showcasing steady export recovery.​

• APIs (Active Pharmaceutical Ingredients):

  • Accounted for 10% of revenue but declined 34.2% YoY due to temporary fire impact at one manufacturing facility in Ankleshwar during FY26 H1.​

 

Management Commentary & Strategic Insights

S. N. Nair, Managing Director, RPG Life Sciences:
“Despite the temporary pressure on API exports, our formulation business continues to grow ahead of industry averages. Domestic performance remains strong, led by our flagship brands like Naprosyn and Azotax. We are investing in expanding capacities, launching new therapeutic portfolios, and exploring synergistic acquisitions to accelerate our journey towards crossing ₹1,000 crore in revenues by FY29.”.​

Strategic Outlook:

• The company is expanding its monoclonal antibodies (MABs) pipeline, exploring launches in rheumatology and nephrology segments.​

• Evaluating entry into trade generics and med-tech collaborations for early detection of chronic kidney disease.​

• RPG Life Sciences maintains a strong cash surplus of ₹223 crore and continues to be debt-free, providing flexibility for inorganic growth.​

• The resignation of CFO Vishal Shah (effective October 23, 2025) is not expected to impact operations materially, as succession planning is already underway.​

 

 

Q1 FY26 Earnings Results

• Revenue: ₹168.9 crore.​

• EBITDA: ₹40.7 crore (margin 24.1%).​

• PAT: ₹26.29 crore.​

• EPS: ₹15.90.​

• Highlights: Growth driven by domestic formulations and steady API recovery after plant revalidation; EBITDA margin steady near 24% indicating stable cost control.

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.